BAGSVAERD, Denmark Novo Nordisk is launching a global survey on the psychological and social effects of hemophilia to mark World Hemophilia Day, which takes place Saturday, the Danish drug maker announced Friday.
The survey will include responses from more than 1,300 people in 12 countries. The first phase will involve 150 face-to-face interviews to identify the most common issues affecting people with the disease. A second phase involving 1,200 respondents will follow. Issues facing those with hemophilia include lack of self-esteem, adverse effects on family life, living with pain and fearing a future with disabilities, Novo Nordisk said.
The initial findings from the study will be presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, between July 10 and 14.
“Hemophilia has far-reaching consequences beyond the physical impact of the condition for people with hemophilia, their families and the people treating the condition,” Novo Nordisk corporate VP global stakeholder engagement Charlotte Ersboll said. “This new program will help us to better understand these broader effects on the hemophilia community.”